Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Fezakinumab (anti-IL-22) (Ab170546) - ELISA
Immobilized Recombinant Human IL-22 Protein at 1 μg/mL can bind Fezakinumab (anti-IL-22) (Ab170546) with the EC₅₀ of 69.72 ng/mL.
Fezakinumab (anti-IL-22) (Ab170546) - SEC
The purity of Fezakinumab (anti-IL-22) (Ab170546) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1101604 | Certificate of Analysis | Nov 08, 2023 | Ab170546 |
| ZJ23F1101605 | Certificate of Analysis | Nov 08, 2023 | Ab170546 |
| 1. Yingjie Shen, Yitong Zhou, Kuziwakwashe Alice Chiwa, Junxin Wang, Shihong Ren, Mingxuan Wang, Hongru Ren, Yeyi Zheng, Ying Yu, Lutao Jiang, Jingmou Yu, Yuchun Qiao, Litai Jin, Jianlin Lou, Xiangkuo Zheng. (2025) MiR•101 and miR•122 Targeting δ-Catenin to Regulate Keratinocyte Responsiveness to IL-17A in Psoriasis. FASEB JOURNAL, 39 (7): (e70539). [PMID:40202916] [10.1096/fj.202500003R] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
